The inflammatory caspases-1 and-11 mediate the pathogenesis of dermatitis in sharpin-deficient mice

Journal of Immunology

Volumn 195, Issue 5, 2015, Pages 2365-2373

  Douglas, Todd ^a   Champagne, Claudia ^b   Morizot, Alexandre ^b   Lapointe, Jean Martin ^a   Saleh, Maya ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 11; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; CARRIER PROTEIN; CASP11 PROTEIN, MOUSE; CASPASE; CIAS1 PROTEIN, MOUSE; SIPL1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DERMATITIS; GENE; GENE LOSS; MACROPHAGE; MOUSE; NLRP3 GENE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; FLUORESCENCE MICROSCOPY; GENETICS; IMMUNOBLOTTING; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NECROSIS; PATHOLOGY; SKIN;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CASPASE 1; CASPASES; DERMATITIS; IMMUNOBLOTTING; INFLAMMASOMES; MACROPHAGES; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; NECROSIS; SIGNAL TRANSDUCTION; SKIN;

EID: 84940118827     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500542     Document Type: Article

References (63)

1. Case, C. L., L. J. Kohler, J. B. Lima, T. Strowig, M. R. de Zoete, R. A. Flavell, D. S. Zamboni, and C. R. Roy. 2013. Caspase-11 stimulates rapid flagellinindependent pyroptosis in response to Legionella pneumophila. Proc. Natl. Acad. Sci. USA 110: 1851-1856.
2. Py, B. F., M. Jin, B. N. Desai, A. Penumaka, H. Zhu, M. Kober, A. Dietrich, M. M. Lipinski, T. Henry, D. E. Clapham, and J. Yuan. 2014. Caspase-11 controls interleukin-1b release through degradation of TRPC1. Cell Reports 6: 1122-1128.
3. Oficjalska, K., M. Raverdeau, G. Aviello, S. C.Wade, A. Hickey, K. M. Sheehan, S. C. Corr, E. W. Kay, L. A. O'Neill, K. H. Mills, and E. M. Creagh. 2015. Protective role for caspase-11 during acute experimental murine colitis. J. Immunol. 194: 1252-1260.
4. Pilla, D. M., J. A. Hagar, A. K. Haldar, A. K. Mason, D. Degrandi, K. Pfeffer, R. K. Ernst, M. Yamamoto, E. A. Miao, and J. Coers. 2014. Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS. Proc. Natl. Acad. Sci. USA 111: 6046-6051.
5. Aachoui, Y., I. A. Leaf, J. A. Hagar, M. F. Fontana, C. G. Campos, D. E. Zak, M. H. Tan, P. A. Cotter, R. E. Vance, A. Aderem, and E. A. Miao. 2013. Caspase-11 protects against bacteria that escape the vacuole. Science 339: 975-978.
6. Meunier, E., M. S. Dick, R. F. Dreier, N. Schürmann, D. Kenzelmann Broz, S. Warming, M. Roose-Girma, D. Bumann, N. Kayagaki, K. Takeda, et al. 2014. Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFNinduced GTPases. Nature 509: 366-370.
7. Casson, C. N., A. M. Copenhaver, E. E. Zwack, H. T. Nguyen, T. Strowig, B. Javdan, W. P. Bradley, T. C. Fung, R. A. Flavell, I. E. Brodsky, and S. Shin. 2013. Caspase-11 activation in response to bacterial secretion systems that access the host cytosol. PLoS Pathog. 9: e1003400.
8. Shi, J., Y. Zhao, Y. Wang, W. Gao, J. Ding, P. Li, L. Hu, and F. Shao. 2014. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514: 187-192.
9. Franklin, B. S., L. Bossaller, D. De Nardo, J. M. Ratter, A. Stutz, G. Engels, C. Brenker, M. Nordhoff, S. R. Mirandola, A. Al-Amoudi, et al. 2014. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat. Immunol. 15: 727-737.
10. Baroja-Mazo, A., F. Martín-Sánchez, A. I. Gomez, C. M. Martínez, J. Amores-Iniesta, V. Compan, M. Barberà-Cremades, J. Yagüe, E. Ruiz-Ortiz, J. Antón, et al. 2014. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 15: 738-748.
11. Savic, S., L. J. Dickie, M. Battellino, and M. F. McDermott. 2012. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr. Opin. Rheumatol. 24: 103-112.
12. Romberg, N., K. Al Moussawi, C. Nelson-Williams, A. L. Stiegler, E. Loring, M. Choi, J. Overton, E. Meffre, M. K. Khokha, A. J. Huttner, et al. 2014. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46: 1135-1139.
13. Canna, S. W., A. A. de Jesus, S. Gouni, S. R. Brooks, B. Marrero, Y. Liu, M. A. DiMattia, K. J. Zaal, G. A. Sanchez, H. Kim, et al. 2014. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46: 1140-1146.
14. Vande Walle, L., N. Van Opdenbosch, P. Jacques, A. Fossoul, E. Verheugen, P. Vogel, R. Beyaert, D. Elewaut, T. D. Kanneganti, G. van Loo, and M. Lamkanfi. 2014. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512: 69-73.
15. Yan, Y., W. Jiang, L. Liu, X. Wang, C. Ding, Z. Tian, and R. Zhou. 2015. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160: 62-73.
16. Nakamura, Y., L. Franchi, N. Kambe, G. Meng, W. Strober, and G. Núñez. 2012. Critical role for mast cells in interleukin-1b-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity 37: 85-95.
17. Yamanaka, K., M. Tanaka, H. Tsutsui, T. S. Kupper, K. Asahi, H. Okamura, K. Nakanishi, M. Suzuki, N. Kayagaki, R. A. Black, et al. 2000. Skin-specific caspase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J. Immunol. 165: 997-1003.
18. Konishi, H., H. Tsutsui, T. Murakami, S. Yumikura-Futatsugi, K. Yamanaka, M. Tanaka, Y. Iwakura, N. Suzuki, K. Takeda, S. Akira, et al. 2002. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA 99: 11340-11345.
19. Bieber, T. 2008. Atopic dermatitis. N. Engl. J. Med. 358: 1483-1494.
20. Palmer, C. N., A. D. Irvine, A. Terron-Kwiatkowski, Y. Zhao, H. Liao, S. P. Lee, D. R. Goudie, A. Sandilands, L. E. Campbell, F. J. Smith, et al. 2006. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38: 441-446.
21. Spergel, J. M., and A. S. Paller. 2003. Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 112(6, Suppl.)S118-S127.
22. Hirota, T., A. Takahashi, M. Kubo, T. Tsunoda, K. Tomita, M. Sakashita, T. Yamada, S. Fujieda, S. Tanaka, S. Doi, et al. 2012. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat. Genet. 44: 1222-1226.
23. Bonnet, M. C., D. Preukschat, P. S. Welz, G. van Loo, M. A. Ermolaeva, W. Bloch, I. Haase, and M. Pasparakis. 2011. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 35: 572-582.
24. Dannappel, M., K. Vlantis, S. Kumari, A. Polykratis, C. Kim, L. Wachsmuth, C. Eftychi, J. Lin, T. Corona, N. Hermance, et al. 2014. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513: 90-94.
25. Weinlich, R., A. Oberst, C. P. Dillon, L. J. Janke, S. Milasta, J. R. Lukens, D. A. Rodriguez, P. Gurung, C. Savage, T. D. Kanneganti, and D. R. Green. 2013. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Reports 5: 340-348.
26. Panayotova-Dimitrova, D., M. Feoktistova, M. Ploesser, B. Kellert, M. Hupe, S. Horn, R. Makarov, F. Jensen, S. Porubsky, A. Schmieder, et al. 2013. cFLIP regulates skin homeostasis and protects against TNF-induced keratinocyte apoptosis. Cell Reports 5: 397-408.
27. Omori, E., K. Matsumoto, H. Sanjo, S. Sato, S. Akira, R. C. Smart, and J. Ninomiya-Tsuji. 2006. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 281: 19610-19617.
28. Tokunaga, F., S. Sakata, Y. Saeki, Y. Satomi, T. Kirisako, K. Kamei, T. Nakagawa, M. Kato, S. Murata, S. Yamaoka, et al. 2009. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat. Cell Biol. 11: 123-132.
29. Peltzer, N., E. Rieser, L. Taraborrelli, P. Draber, M. Darding, B. Pernaute, Y. Shimizu, A. Sarr, H. Draberova, A. Montinaro, et al. 2014. HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Reports 9: 153-165.
30. Seymour, R. E., M. G. Hasham, G. A. Cox, L. D. Shultz, H. Hogenesch, D. C. Roopenian, and J. P. Sundberg. 2007. Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 8: 416-421.
31. Gerlach, B., S. M. Cordier, A. C. Schmukle, C. H. Emmerich, E. Rieser, T. L. Haas, A. I. Webb, J. A. Rickard, H. Anderton, W. W. Wong, et al. 2011. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471: 591-596.
32. Tokunaga, F., T. Nakagawa, M. Nakahara, Y. Saeki, M. Taniguchi, S. Sakata, K. Tanaka, H. Nakano, and K. Iwai. 2011. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 471: 633-636.
33. Ikeda, F., Y. L. Deribe, S. S. Skånland, B. Stieglitz, C. Grabbe, M. Franz-Wachtel, S. J. van Wijk, P. Goswami, V. Nagy, J. Terzic, et al. 2011. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 471: 637-641.
34. Gijbels, M. J., C. Zurcher, G. Kraal, G. R. Elliott, H. HogenEsch, G. Schijff, H. F. Savelkoul, and P. L. Bruijnzeel. 1996. Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm). Am. J. Pathol. 148: 941-950.
35. HogenEsch, H., S. E. Torregrosa, D. Boggess, B. A. Sundberg, J. Carroll, and J. P. Sundberg. 2001. Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12. Eur. J. Immunol. 31: 734-742.
36. Renninger, M. L., R. E. Seymour, L. O. Whiteley, J. P. Sundberg, and H. Hogenesch. 2010. Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice. Exp. Dermatol. 19: 252-258.
37. Potter, C. S., Z. Wang, K. A. Silva, V. E. Kennedy, T. M. Stearns, L. Burzenski, L. D. Shultz, H. Hogenesch, and J. P. Sundberg. 2014. Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling. PLoS One 9: e85666.
38. Beck, L. A., D. Thaçi, J. D. Hamilton, N. M. Graham, T. Bieber, R. Rocklin, J. E. Ming, H. Ren, R. Kao, E. Simpson, et al. 2014. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371: 130-139.
39. Berger, S. B., V. Kasparcova, S. Hoffman, B. Swift, L. Dare, M. Schaeffer, C. Capriotti, M. Cook, J. Finger, A. Hughes-Earle, et al. 2014. Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J. Immunol. 192: 5476-5480.
40. Liang, Y., R. E. Seymour, and J. P. Sundberg. 2011. Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice. J. Invest. Dermatol. 131: 141-149.
41. Kuida, K., J. A. Lippke, G. Ku, M. W. Harding, D. J. Livingston, M. S. Su, and R. A. Flavell. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267: 2000-2003.
42. Mariathasan, S., D. S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W. P. Lee, Y. Weinrauch, D. M. Monack, and V. M. Dixit. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
43. Labbé, K., C. R. McIntire, K. Doiron, P. M. Leblanc, and M. Saleh. 2011. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 35: 897-907.
44. Kumari, S., Y. Redouane, J. Lopez-Mosqueda, R. Shiraishi, M. Romanowska, S. Lutzmayer, J. Kuiper, C. Martinez, I. Dikic, M. Pasparakis, and F. Ikeda. 2014. Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis. eLife Dec 2; 3.
45. Rickard, J. A., H. Anderton, N. Etemadi, U. Nachbur, M. Darding, N. Peltzer, N. Lalaoui, K. E. Lawlor, H. Vanyai, C. Hall, et al. 2014. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. eLife Dec 2; 3.
46. Kayagaki, N., S. Warming, M. Lamkanfi, L. Vande Walle, S. Louie, J. Dong, K. Newton, Y. Qu, J. Liu, S. Heldens, et al. 2011. Non-canonical inflammasome activation targets caspase-11. Nature 479: 117-121.
47. de Rivero Vaccari, J. P., M. E. Sawaya, F. Brand, III, B. P. Nusbaum, A. J. Bauman, H. M. Bramlett, W. D. Dietrich, and R. W. Keane. 2012. Caspase-1 level is higher in the scalp in androgenetic alopecia. Dermatol. Surg. 38: 1033-1039.
48. Gurung, P., M. Lamkanfi, and T. D. Kanneganti. 2015. Cutting edge: SHARPIN is required for optimal NLRP3 inflammasome activation. J. Immunol. 194: 2064-2067.
49. Kaczmarek, A., P. Vandenabeele, and D. V. Krysko. 2013. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38: 209-223.
50. Sollberger, G., G. E. Strittmatter, S. Grossi, M. Garstkiewicz, U. Auf dem Keller, L. E. French, and H. D. Beer. 2015. Caspase-1 activity is required for UVBinduced apoptosis of human keratinocytes. J. Invest. Dermatol. 135: 1395-1404.
51. Allam, R., K. E. Lawlor, E. C. Yu, A. L. Mildenhall, D. M. Moujalled, R. S. Lewis, F. Ke, K. D. Mason, M. J. White, K. J. Stacey, et al. 2014. Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but nonapoptotic caspase-8 is required for inflammasome priming. EMBO Rep. 15: 982-990.
52. Yabal, M., N. Müller, H. Adler, N. Knies, C. J. Groß, R. B. Damgaard, H. Kanegane, M. Ringelhan, T. Kaufmann, M. Heikenwälder, et al. 2014. XIAP restricts TNF-and RIP3-dependent cell death and inflammasome activation. Cell Reports 7: 1796-1808.
53. Gurung, P., P. K. Anand, R. K. Malireddi, L. Vande Walle, N. Van Opdenbosch, C. P. Dillon, R. Weinlich, D. R. Green, M. Lamkanfi, and T. D. Kanneganti. 2014. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J. Immunol. 192: 1835-1846.
54. Wang, X., W. Jiang, Y. Yan, T. Gong, J. Han, Z. Tian, and R. Zhou. 2014. RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway. Nat. Immunol. 15: 1126-1133.
55. Kang, T. B., S. H. Yang, B. Toth, A. Kovalenko, and D. Wallach. 2013. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38: 27-40.
56. Wu, Y. H., W. C. Kuo, Y. J. Wu, K. T. Yang, S. T. Chen, S. T. Jiang, C. Gordy, Y. W. He, and M. Z. Lai. 2014. Participation of c-FLIP in NLRP3 and AIM2 inflammasome activation. Cell Death Differ. 21: 451-461.
57. Boisson, B., E. Laplantine, C. Prando, S. Giliani, E. Israelsson, Z. Xu, A. Abhyankar, L. Israel, G. Trevejo-Nunez, D. Bogunovic, et al. 2012. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat. Immunol. 13: 1178-1186.
58. HogenEsch, H., M. J. Gijbels, E. Offerman, J. van Hooft, D. W. van Bekkum, and C. Zurcher. 1993. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am. J. Pathol. 143: 972-982.
59. Gijbels, M. J., H. HogenEsch, P. L. Bruijnzeel, G. R. Elliott, and C. Zurcher. 1995. Maintenance of donor phenotype after full-thickness skin transplantation from mice with chronic proliferative dermatitis (cpdm/cpdm) to C57BL/Ka and nude mice and vice versa. J. Invest. Dermatol. 105: 769-773.
60. Gurung, P., R. Karki, P. Vogel, M. Watanabe, M. Bix, M. Lamkanfi, and T. D. Kanneganti. 2015. An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis. J. Clin. Invest. 125: 1329-1338.
61. Harada, M., K. Obara, T. Hirota, T. Yoshimoto, Y. Hitomi, M. Sakashita, S. Doi, A. Miyatake, K. Fujita, T. Enomoto, et al. 2009. A functional polymorphism in IL-18 is associated with severity of bronchial asthma. Am. J. Respir. Crit. Care Med. 180: 1048-1055.
62. Kou, K., M. Aihara, T. Matsunaga, H. Chen, M. Taguri, S. Morita, H. Fujita, Y. Yamaguchi, T. Kambara, and Z. Ikezawa. 2012. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch. Dermatol. Res. 304: 305-312.
63. Trzeciak, M., J. Gleń, T. Bandurski, M. Sokolowska-Wojdylo, A. Wilkowska, and J. Roszkiewicz. 2011. Relationship between serum levels of interleukin-18, IgE and disease severity in patients with atopic dermatitis. Clin. Exp. Dermatol. 36: 728-732.